Repertoire of kinase rearrangements in Ph-like ALL along with their partner genes and potential therapeutic targets
| Kinases . | 5′ partner genes (number of patients) . | Potential TKI . | Clinical trials . |
|---|---|---|---|
| ABL1 | ETV6 (3), NUP214 (6), RCSD1 (1), RANBP2 (1), SNX2 (1), ZMIZ1 (2) | Dasatinib | AALL1131 |
| ABL2 | PAG1 (1), RCSD1 (4), ZC3HAV1 (2) | Dasatinib | AALL1131 |
| PDGFRB | EBF1 (6), SSBP2 (1), TNIP1 (1), ZEB2 (1) | Dasatinib | AALL1131 |
| CSF1R | SSBP2 (4) | Dasatinib | AALL1131 |
| CRLF2 | IGH (19), P2RY8 (11) | Ruxolitinib | AALL1521 |
| JAK2 | ATF7IP (1), BCR (2), EBF1 (1), ETV6 (2), PAX5 (7), PPFIBP1 (1), SSBP2 (2), STRN3 (1), TERF2 (1), TPR (1) | Ruxolitinib | AALL1521 |
| EPOR | IGH (7), IGK (2) | Ruxolitinib | AALL1521 |
| TSLP | IQGAP2 (1) | Ruxolitinib | AALL1521 |
| IL2RB | MYH9 (1) | JAK1/JAK3 inhibitor | N/A |
| TYK2 | MYB (1) | TYK2 inhibitor | N/A |
| NTRK3 | ETV6 (1) | Crizotinib | N/A |
| PTK2B | KDM6A (1), STAG2 (1) | FAK inhibitor | N/A |
| DGKH | ZFAND3 (1) | Unknown | N/A |
| Kinases . | 5′ partner genes (number of patients) . | Potential TKI . | Clinical trials . |
|---|---|---|---|
| ABL1 | ETV6 (3), NUP214 (6), RCSD1 (1), RANBP2 (1), SNX2 (1), ZMIZ1 (2) | Dasatinib | AALL1131 |
| ABL2 | PAG1 (1), RCSD1 (4), ZC3HAV1 (2) | Dasatinib | AALL1131 |
| PDGFRB | EBF1 (6), SSBP2 (1), TNIP1 (1), ZEB2 (1) | Dasatinib | AALL1131 |
| CSF1R | SSBP2 (4) | Dasatinib | AALL1131 |
| CRLF2 | IGH (19), P2RY8 (11) | Ruxolitinib | AALL1521 |
| JAK2 | ATF7IP (1), BCR (2), EBF1 (1), ETV6 (2), PAX5 (7), PPFIBP1 (1), SSBP2 (2), STRN3 (1), TERF2 (1), TPR (1) | Ruxolitinib | AALL1521 |
| EPOR | IGH (7), IGK (2) | Ruxolitinib | AALL1521 |
| TSLP | IQGAP2 (1) | Ruxolitinib | AALL1521 |
| IL2RB | MYH9 (1) | JAK1/JAK3 inhibitor | N/A |
| TYK2 | MYB (1) | TYK2 inhibitor | N/A |
| NTRK3 | ETV6 (1) | Crizotinib | N/A |
| PTK2B | KDM6A (1), STAG2 (1) | FAK inhibitor | N/A |
| DGKH | ZFAND3 (1) | Unknown | N/A |
Adapted from Roberts et al,6 with permission.